Corline Biomedical AB

Stockholm Stock Exchange CLBIO.ST

Corline Biomedical AB Capital Expenditure for the year ending December 31, 2023: USD -1.05 M

Corline Biomedical AB Capital Expenditure is USD -1.05 M for the year ending December 31, 2023, a -21.98% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Corline Biomedical AB Capital Expenditure for the year ending December 31, 2022 was USD -859.40 K, a 18.83% change year over year.
Corline Biomedical AB Capital Expenditure for the year ending December 31, 2021 was USD -1.06 M, a 0.72% change year over year.
Corline Biomedical AB Capital Expenditure for the year ending December 31, 2020 was USD -1.07 M, a -106.94% change year over year.
Corline Biomedical AB Capital Expenditure for the year ending December 31, 2019 was USD -515.40 K, a -388.94% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Stockholm Stock Exchange: CLBIO.ST

Corline Biomedical AB

CEO	Dr. Henrik Nittmar Ph.D.
IPO Date	June 3, 2015
Location	Sweden
Headquarters	Lefflersgatan 5
Employees	13
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.

Key trends

Past 5 years